Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.

ABSTRACT:

Background

Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter in tumor progression and metastasis of HNSCC. However, Src therapy for HNSCC is limited by lack of efficient in vivo delivery and underlying mechanisms remain elusive.

Methods

Src knockdown cells were achieved by lentiviral-mediated interference. Cell migration and invasion were examined by wound healing and Transwell assays. Protein levels were determined by Western blot and/or immunohistochemistry. The Src inhibitor saracatinib was loaded into self-assembling nanoparticles by the solvent evaporation method. An experimental metastasis mouse model was genera

SUBMITTER: Lang L 

PROVIDER: S-EPMC6011403 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature